Wingard 2010.

Study characteristics
Methods	Randomization in a 1:1 ratio in permuted blocks (size not stated).
Participants	600 patients with leukaemia or other haematopoietic disorders receiving allogeneic haematopoietic stem cell transplantation treated prophylactically with either voriconazole or fluconazole.
Interventions	Voriconazole: 200 mg orally twice daily for 100 days. Fluconazole 400 mg once daily for 100 days.
Outcomes	Primary outcome: Fungal free survival at 180 days Secondary outcomes: incidence of invasive fungal infections. Time to invasive fungal infections. Six month and 1 year relapse free survival. Overall survival. Time to and duration of empiric antifungal therapy. Frequency of adverse events. Incidence of acute or chronic graft‐versus‐host disease
Notes	The follow‐up period was 180 days and 1 year Supported by a grant from the National Institutes of Health and an "unrestricted educational grant" from Pfizer
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	1:1 permutated blocks, unclear if allocation concealment was obtained
Blinding (performance bias and detection bias) All outcomes	Low risk	The clinician, patient and the data review board were blinded